If You Invested in Moolec Science SA (MLEC)
See the MLEC overviewWhat $1,000 or $10,000 in MLEC Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Mar 3, 2021 |
|---|---|---|---|---|
| $1,000 | $87 -91% | $0.57 -99.94% | — | $0.58 -99.94% |
| $10,000 | $873 -91% | $5.74 -99.94% | — | $5.75 -99.94% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-02. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for MLEC$1,000 Investment Over Time
MLEC vs S&P 500Year-by-Year Returns
MLEC annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021Mar 3 to Dec 31 | $1,477.50 | $1,479.00 | +0.1% | +0.1% |
| 2022 | $1,479.00 | $1,815.00 | +22.7% | +22.8% |
| 2023 | $1,815.00 | $369.00 | -79.7% | -75.0% |
| 2024 | $369.00 | $120.00 | -67.5% | -91.9% |
| 2025 | $120.00 | $3.82 | -96.8% | -99.7% |
| 2026Dec 31, 2025 to Nov 2 | $3.82 | $0.85 | -77.7% | -99.9% |
About Moolec Science SA
Healthcare · NASDAQ
Moolec Science SA (NASDAQ: MLEC) is a science-based food ingredient and life sciences company that focuses on producing animal proteins, nutritional oils, and other functional ingredients in plants and microbes. According to the company’s public statements, Moolec engineers plants and microbes to unlock scalable protein solutions for the global food system, integrating Molecular Farming with precision fermentation to combine the cost efficiency of crops with the functionality and nutrition of animal proteins. Its shares trade on the Nasdaq Capital Market under the ticker symbol MLEC.
Business focus and technology platforms
Moolec describes itself as an innovation-driven company that uses plant engineering and microbial technologies to create ingredients for the food and agriculture value chain. By integrating Molecular Farming and precision fermentation, the company aims to generate sustainable and commercially viable ingredients that can be produced at scale. Public disclosures state that Moolec’s diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture.
The company reports that it has a significant intellectual property position, with more than 118 granted and pending patents across multiple technology platforms. This portfolio is intended to protect its Molecular Farming innovations, precision fermentation developments, and related ingredient technologies.
Molecular Farming and plant-based ingredient programs
Moolec’s ingredient programs include plant-based systems designed to express animal proteins and specialty lipids directly in crops. The company has disclosed a pipeline that historically included products such as TSP Valorasoy (a soy protein product), Glaso (a safflower oil with high levels of gamma-linolenic acid), SPC2 (a plant-based chymosin), and YEEA1 (an extract derived from a novel yeast biomass). In more recent communications, Moolec has emphasized its GLASO safflower platform and Piggy Sooy™ technology as key Molecular Farming assets.
The GLASO safflower platform is described as a proprietary crop enriched in gamma-linolenic acid (GLA), a specialty oil with nutritional and industrial applications. Moolec has reported regulatory approval in Argentina for its safflower GLASO technology for feed and food use, enabling expansion of this crop and supporting counter-season supply strategies. The company has also highlighted expansion of U.S. acreage dedicated to GLASO production to support revenue-generating activities and to build commercial inventory for customers in sectors such as pet food and human nutrition.
Piggy Sooy™ is described as a soybean plant engineered to express high levels of porcine hemeproteins in its seeds. Moolec has announced that it received a Notice of Allowance from the United States Patent and Trademark Office for this technology, covering the plants and seeds, the method used to develop them, and food compositions derived from them. The company reports that initial field trials demonstrated promising production yield and high animal protein content in the soluble protein fraction, and that U.S. regulatory authorities determined Piggy Sooy™ is not subject to certain plant pest regulations, which Moolec views as a milestone toward commercialization.
Precision fermentation and expanded life sciences platform
Through a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, Moolec has described an expanded platform that spans food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services. Following the closing of this business combination, Moolec stated that it would continue operating under the Moolec Science name as the parent company of an enlarged enterprise focused on sustainable solutions from molecule to ingredient.
As part of this transaction and subsequent integration, Moolec has highlighted the incorporation of Mycofood™ as a dedicated platform for fungal-based alternative proteins via precision fermentation, with applications under evaluation by food industry partners in North America and Europe. The company positions this fungal protein platform as complementary to its Molecular Farming programs, broadening its protein technology portfolio.
Ag-biologicals, regenerative agriculture, and biomaterials
In connection with the business combination, Moolec has indicated that it will offer upstream technologies for regenerative agriculture through brands associated with Bioceres Group, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands. The company also references activities in emerging technologies for grain and biomass transformation, particularly in the biomaterials space, and new concepts in farm equipment that integrate material science, electric mobility, and autonomy, developed through subsidiaries of Gentle Tech and Bioceres Group.
Moolec has stated that its pipeline includes biological inputs for regenerative agriculture, aligning its ingredient and technology development with agricultural practices that seek to improve soil health and resource efficiency. These capabilities are supported by R&D and technical infrastructure platforms such as Agrality® and Synbio Powerlabs®, which Moolec describes as providing in-house R&D, contract development and manufacturing (CDMO), and regulatory capabilities to accelerate technology development and regulatory progression.
Operational footprint and markets
According to company disclosures, Moolec has operations spanning the United States, Europe, and South America. Earlier descriptions indicated that the company’s maximum revenues from operations were in Argentina. Subsequent press releases emphasize activities in the United States (including GLASO safflower campaigns and acreage expansion), regulatory approvals and potential counter-season supply strategies in Argentina, and commercial development and partnerships in North America and Europe for its protein and lipid ingredients.
Moolec has reported that it is engaging with organizations in the pet food and human nutrition industries, as well as wellness and performance brands in the nutrition and supplements market, particularly in relation to its GLASO safflower oil platform. The company has also indicated interest in high-concentration GLA softgel applications and access to established softgel distribution channels, positioning GLASO-derived ingredients for use in high-value nutritional markets.
Capital markets, listing status, and share structure
Moolec Science SA is publicly listed on the Nasdaq Capital Market under the symbol MLEC, with publicly traded warrants under the symbol MLECW. The company has disclosed several capital markets and listing-related developments.
Moolec has reported receiving determination letters from Nasdaq related to compliance with listing rules, including the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), the timely filing of its Annual Report on Form 20-F, and the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). In each case, the company has publicly stated its intent to appeal or address these matters, including by requesting hearings before a Nasdaq Hearings Panel and by working to complete required filings.
To support compliance with Nasdaq listing standards, the company has implemented share structure changes. Moolec announced a reverse stock split (share consolidation) at a ratio of one-for-ten, reducing the number of issued and outstanding ordinary shares while maintaining the same par value per share. Later, Moolec’s shareholders approved, and the board implemented, a further share consolidation at a ratio of 15-for-1, consolidating every 15 ordinary shares of par value US$0.10 into one ordinary share of par value US$1.50. The company has stated that these consolidations do not affect its business or operations but are intended, among other purposes, to help regain compliance with Nasdaq’s minimum bid price requirement.
Moolec has also disclosed that it received a staff determination letter regarding the minimum stockholders’ equity requirement and that management expects to regain compliance through recognition of an accounting gain related to the derecognition of certain subsidiaries following bankruptcy proceedings. The company has indicated that this derecognition process is underway.
Corporate structure and jurisdiction
Moolec Science SA is described in SEC filings as a public limited liability company incorporated under the laws of the Cayman Islands, with principal executive offices in Grand Cayman, Cayman Islands. The company files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports.
Intellectual property and regulatory milestones
The company emphasizes its intellectual property portfolio, stating that it holds more than 118 granted and pending patents across multiple technology platforms. These include patents related to Molecular Farming innovations such as Piggy Sooy™ and GLASO™, as well as precision fermentation and related life sciences technologies.
Regulatory milestones disclosed by Moolec include the U.S. regulatory determination that Piggy Sooy™ does not present a plant pest risk difference from conventional soybeans under specific regulations, and feed and food approval in Argentina for its safflower GLASO technology. These regulatory decisions are presented by the company as important steps toward commercialization and expansion of its ingredient platforms.
Position within the food-tech and life sciences landscape
Through its combination of Molecular Farming, precision fermentation, ag-biologicals, and biomaterials initiatives, Moolec positions itself at the intersection of biotechnology and food production. Public communications describe the company as focusing on sustainable life sciences and food-tech innovation, with a seed-to-ingredient approach designed to transform aspects of food production and agricultural inputs.
Moolec’s activities span ingredient innovation (such as Piggy Sooy™, GLASO™, and Mycofood™), biological inputs and climate-smart seeds, and technical services through R&D and CDMO platforms. The company presents these elements as part of an integrated life science platform intended to support sustainable growth and long-term value creation within the food and agriculture sectors.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Moolec Science SA investment returns
How much was $1,000 invested in Moolec Science SA worth at its last close?
If you invested $1,000 in Moolec Science SA (MLEC) 5 years before its last close, on 2021-11-02, your investment was worth $0.57 on 2026-11-02, a -99.9% price return without dividends, growing at a compounded rate of -77.5% per year (CAGR).
Has Moolec Science SA outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare MLEC performance over available time periods.
What is Moolec Science SA's average annual return?
The compound annual growth rate (CAGR) of MLEC’s share price over the 5 years to Nov 2, 2026 is -77.5%, without dividends. Individual years vary a great deal, and MLEC’s best recent full year was 2022 (+22.7%) while the worst was 2025 (-96.8%).
For informational and educational purposes only, not investment advice.